NEWARK, N.J. and CRANBURY N.J., June 23,
2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL)
and Rafael Pharmaceuticals today announced that Ameet Mallik, CEO of Rafael Holdings, Inc.,
Sanjeev Luther, President & CEO
of Rafael Pharmaceuticals, and Tim
Pardee, Co-Chief Medical Officer of Rafael Pharmaceuticals,
presented at the Raymond James 2021 Human Health Innovation
Conference on June 22, 2021.
A replay of the audio webcast of the presentation and
accompanying slide presentation are available on the "Events &
Presentations" page within the Investors section of the Rafael
Holdings website or by using the link below.
Webcast:
https://kvgo.com/rj-health/rafael-pharmaceuticals-june-2021
About Rafael Holdings, Inc.:
Rafael Holdings (NYSE: RFL) is focused on the development of
novel cancer therapies. The Company is a significant investor
in two clinical stage oncology companies-- Rafael Pharmaceuticals,
Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly
owned Barer Institute subsidiary, the Company is developing a
pipeline of compounds focused on the regulation of cancer
metabolism. On June 21, 2021,
Rafael Holdings, Inc., (NYSE: RFL) announced that it has entered
into a merger agreement with Rafael Pharmaceuticals, Inc., to
create a publicly traded late-stage clinical oncology company
focused on cancer metabolism-based therapeutics. For more
information, visit www.rafaelholdings.com.
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals is a clinical-stage oncology company
focused on selectively targeting cancer metabolic pathways while
simultaneously harnessing the immune system to attack hard-to-treat
cancers. The Company's lead drug, CPI-613 (devimistat), is being
evaluated in multiple clinical studies including two Phase 3
registrational clinical trials for metastatic pancreatic cancer and
r/r acute myeloid leukemia. Multiple Phase 1/2 clinical trials are
ongoing or planned in Biliary, r/r Burkitt, r/r Clear Cell Sarcoma,
r/r T-cell lymphoma, r/r MDS, and Colorectal cancer.
Devimistat has Orphan Drug Designations for six indications in
the US and two indications in the EU. The Company's investors
include Rafael Holdings, Inc. (NYSE: RFL). For more information,
please visit https://rafaelpharma.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements relate to future events or the company's future
financial performance. In some cases, you can identify
forward-looking statements by terminology such as "may", "will",
"should", "expect", "plan", "anticipate", "believe", "estimate",
"predict", "potential" or "continue", the negative of such terms,
or other comparable terminology. These statements are only
predictions. Actual events or results may differ materially from
those in the forward-looking statements as a result of various
important factors. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, such
statements should not be regarded as a representation by the
company, or any other person, that such forward-looking statements
will be achieved. The business and operations of the company are
subject to substantial risks which increase the uncertainty
inherent in forward-looking statements. We undertake no duty to
update any of the forward-looking statements, whether as a result
of new information, future events or otherwise.
In light of the foregoing, readers are cautioned not to place
undue reliance on such forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rafael-holdings-and-rafael-pharmaceuticals-management-presented-at-the-raymond-james-2021-human-health-innovation-conference-on-june-22-2021-301318625.html
SOURCE Rafael Holdings, Inc.